Silexion Therapeutics has launched a Phase 2/3 clinical trial for SIL204 to treat pancreatic cancer, following regulatory approvals in Israel and Germany. The trial, initiated at Tel Aviv Sourasky Medical Center, is supported by a recent $2.5 million public offering, vital for advancing its clinical program.

Key Highlights

  • Silexion Therapeutics has commenced a Phase 2/3 clinical program for SIL204 in advanced pancreatic cancer, initiating at Tel Aviv Sourasky Medical Center on July 29, 2026.
  • The company reported net loss of approximately $3.6 million for Q2 2026, up 44.0% from the same quarter in 2025.
  • A public offering raised gross proceeds of about $2.5 million on August 13, 2026, important for funding the clinical trial and enhancing the balance sheet.

Silexion Therapeutics Corp. has successfully transitioned its candidate SIL204 into a Phase 2/3 clinical trial targeting locally advanced pancreatic cancer, with trial initiation occurring on July 29, 2026, at Tel Aviv Sourasky Medical Center. The overlapping authorizations demonstrate Silexion’s strategic approach to streamlining its clinical development process across two important markets, underscoring a strong trajectory toward fulfilling unmet medical needs in pancreatic cancer treatment.

Regulatory Approvals and Clinical Readiness

In July 2026, Silexion not only obtained the green light from health authorities in both Germany and Israel but also commenced patient screening at one of Israel's top academic medical centers. The success in these regulatory processes was preceded by the submission of a Clinical Trial Application to BfArM in April 2026. Future trials are also expected to expand to additional sites in Israel and Germany, amplifying patient inclusion in upcoming phases.

Financial Performance Underlines Growth Strategy

During the second quarter of 2026, Research and Development (R&D) expenses reached approximately $2.2 million, representing a substantial increase of 120.0% compared to the prior year. This increase reflects heightened operational activities necessary to support the clinical trial infrastructure for SIL204. General and administrative (G&A) expenses amounted to approximately $1.5 million, which is a 15.4% rise from the same period in 2025, primarily driven by increased professional services costs.

The increase in expenditures aligns with Silexion's accelerated focus on clinical activities amid preparations for the Phase 2/3 trial.

Funding Moves to Fortify Financial Health

Silexion succeeded in a public offering dated August 13, 2026, raising gross proceeds of approximately $2.5 million, aimed at bolstering its Balance Sheet as it gears up for the clinical trial. This offering adds to a series of financing actions, including Warrant inducements and Share Capital increases conducted to comply with Nasdaq listing requirements. The total net proceeds are approximately $2.1 million, enhancing Liquidity as Silexion advances its ambitious clinical program.

This financial maneuvering not only provides immediate capital support but also illustrates the company’s commitment to maintaining its operational momentum while ensuring compliance with exchange regulations.

Upcoming Developments to Monitor

The recently initiated Phase 2/3 clinical trial represents a key moment for Silexion as it aims to make meaningful advancements in the treatment of pancreatic cancer. With patient screening underway and several additional trial sites expected to activate soon, Silexion now focuses on executing the trial successfully. Continuous monitoring of the trial's progress, patient dosing schedules, and any regulatory updates will be critical for Stakeholders looking to gauge the efficacy and future potential of SIL204 in the therapeutic environment for pancreatic cancer.